MARC GARFIELD: Open Payments
NPI 1407899586 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$766 in 34 payments from 15 companies in 2025. Trend: 2023 $67 · 2024 $650 · 2025 $766
Food & beverage: $667Education: $99
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $163 |
| Astellas Pharma US Inc | 4 | $146 |
| Sumitomo Pharma America, Inc. | 4 | $75 |
| Braeburn Inc. | 3 | $72 |
| Lilly USA, LLC | 3 | $64 |
| KVK-Tech, Inc. | 1 | $45 |
| ABBVIE INC. | 2 | $36 |
| Amgen Inc. | 2 | $35 |
| PFIZER INC. | 1 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
Products named: GEMTESA, BRIXADI, MOUNJARO, AIRSUPRA, Veozah, LOKELMA, BREZTRI, VRAYLAR.
Industry payments across PA — which companies pay providers there.
